Clinical data
ATC code None
Legal status
Legal status
  • Investigational
PubChem (CID) 25195495
ChemSpider 25069706
Chemical and physical data
Formula C26H24FN3O3S
Molar mass 477.549 g/mol (free base)
3D model (Jmol) Interactive image

SB-649868 is a dual orexin receptor antagonist in development by GlaxoSmithKline.[1] The drug is currently in phase II development for insomnia.

A phase I study evaluated doses up to 80 mg, resulting in significant improvement in sleep latency without adverse effects.[2]

In randomized, double-blind, placebo-controlled crossover trials, the 10 and 30 mg doses increased sleep time and reduced sleep latency.[3] The subsequent study added a 60 mg dose and observed dose-dependent sleep promotion.[4]

See also


  1. Renzulli C; Nash M; Wright M; Thomas S; Zamuner S; Pellegatti M; Bettica P; Boyle G (February 2011). "Disposition and metabolism of [14C]SB-649868, an orexin 1 and 2 receptor antagonist, in humans" (PDF). Drug Metab. Dispos. 39 (2): 215–27. doi:10.1124/dmd.110.035386. PMID 21045199.
  2. "Phase I studies on the safety, tolerability, pharmacokinetics and pharmacodynamics of SB-649868, a novel dual orexin receptor antagonist.". Journal of Psychopharmacology. 26: 1058–1070. Aug 2012. doi:10.1177/0269881111408954. PMID 21730017.
  3. "Differential effects of a dual orexin receptor antagonist (SB-649868) and zolpidem on sleep initiation and consolidation, SWS, REM sleep, and EEG power spectra in a model of situational insomnia.". Neuropsychopharmacology. 37: 1224–33. Apr 2012. doi:10.1038/npp.2011.310. PMID 22237311.
  4. "The orexin antagonist SB-649868 promotes and maintains sleep in men with primary insomnia.". Sleep. 35: 1097–104. Aug 2012. doi:10.5665/sleep.1996. PMID 22851805.

Further reading

This article is issued from Wikipedia - version of the 9/7/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.